학술논문

Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors
Document Type
Journal
Source
CANCER RESEARCH; APR 15 2023, 83 8, 3p. Supplement: S
Subject
Language
English
ISSN
15387445